| 1 |
Escribano-Subias P, Blanco I, López-Meseguer M, et al. Survival in pulmonary hypertension in Spain: insights from the Spanish registry[J]. Eur Respir J, 2012, 40(3): 596-603.
|
| 2 |
Savale L, Guimas M, Ebstein N, et al. Portopulmonary hypertension in the current era of pulmonary hypertension management[J]. J Hepatol, 2020, 73(1): 130-139.
|
| 3 |
蔡均均，韩涛. 门脉性肺动脉高压的诊断与治疗进展[J]. 实用肝脏病杂志，2014, 17(2): 214-217.
|
| 4 |
AbuHalimeh B, Krowka MJ, Tonelli AR. Treatment barriers in portopulmonary hypertension[J]. Hepatology, 2019, 69(1): 431-443.
|
| 5 |
Deroo R, Trépo E, Holvoet T, et al. Vasomodulators and liver transplantation for portopulmonary hypertension: evidence from a systematic review and meta-analysis[J]. Hepatology, 2020, 72(5): 1701-1716.
|
| 6 |
Preston IR, Burger CD, Bartolome S, et al. Ambrisentan in portopulmonary hypertension: a multicenter, open-label trial[J]. J Heart Lung Transplant, 2020, 39(5): 464-472.
|
| 7 |
Savale L, Sattler C, Coilly A, et al. Long-term outcome in liver transplantation candidates with portopulmonary hypertension[J]. Hepatology, 2017, 65(5): 1683-1692.
|
| 8 |
Thomas C, Glinskii V, de Jesus Perez V, et al. Portopulmonary hypertension: from bench to bedside[J]. Front Med (Lausanne), 2020, 7: 569413.
|
| 9 |
中华医学会器官移植学分会围手术期管理学组，中国医师协会外科医师分会器官移植围手术期管理专业委员会. 门静脉性肺动脉高压肝移植围手术期管理中国专家共识(2021版)[J]. 中华消化外科杂志，2022, 21(1): 10-14.
|
| 10 |
Cosarderelioglu C, Cosar AM, Gurakar M, et al. Portopulmonary hypertension and liver transplant: recent review of the literature[J]. Exp Clin Transplant, 2016, 14(2): 113-120.
|
| 11 |
Al-Naamani N, Krowka MJ, Forde KA, et al. Estrogen signaling and portopulmonary hypertension: the Pulmonary Vascular Complications of Liver Disease Study (PVCLD2) [J]. Hepatology, 2021, 73(2): 726-737.
|
| 12 |
孙丽莹，董冲，潘澄，等. 重度门脉性肺动脉高压患者经长期使用依前列醇治疗后成功接受肝移植术一例[J]. 中华器官移植杂志，2008, 29(6): 376-377.
|
| 13 |
徐杰，史阳阳，孙凯. 门脉性肺动脉高压发病机制及治疗的最新研究进展[J]. 医学综述，2021, 27(13): 2503-2508.
|